---
title: "Anbio Biotechnology (NNNN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NNNN.US.md"
symbol: "NNNN.US"
name: "Anbio Biotechnology"
industry: "Biotechnology"
datetime: "2026-05-19T20:26:40.721Z"
locales:
  - [en](https://longbridge.com/en/quote/NNNN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NNNN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NNNN.US.md)
---

# Anbio Biotechnology (NNNN.US)

## Company Overview

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.anbiobiotechnology.com](https://www.anbiobiotechnology.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: B (0.34)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 25 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5.64% |  |
| Net Profit YoY | 169.86% |  |
| P/B Ratio | 134.32 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4050537280.00 |  |
| Revenue | 8646844.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 27.05% | A |
| Profit Margin | 74.06% | A |
| Gross Margin | 87.24% | A |
| Revenue YoY | 5.64% | C |
| Net Profit YoY | 169.86% | A |
| Total Assets YoY | 59.83% | A |
| Net Assets YoY | 75.41% | A |
| Cash Flow Margin | -105.24% | E |
| OCF YoY | 5.64% | C |
| Turnover | 0.35 | D |
| Gearing Ratio | 0.29% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Anbio Biotechnology",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "5.64%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "169.86%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "134.32",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4050537280.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8646844.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "27.05%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "74.06%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "87.24%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "5.64%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "169.86%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "59.83%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "75.41%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-105.24%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "5.64%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "0.29%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 632.55 | 60/386 | 1423.76 | 814.99 | 492.03 |
| PB | 134.32 | 444/386 | 135.01 | 119.66 | 67.91 |
| PS (TTM) | 468.44 | 286/386 | 512.76 | 268.87 | 142.64 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NNNN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NNNN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NNNN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NNNN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**